Diabetic macular edema

Developments in Ophthalmology

Volumn 58, Issue , 2017, Pages 102-138

  Bandello, Francesco ^a   Battaglia Parodi, Maurizio ^a   Lanzetta, Paolo ^b   Loewenstein, Anat ^c   Massin, Pascale ^d   Menchini, Francesca ^b   Veritti, Daniele ^b  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b UNIVERSITY OF UDINE   (Italy)

^c TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^d HÔPITAL LARIBOISIÈRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DIABETIC RETINOPATHY; DISEASE MANAGEMENT; GLOBAL HEALTH; HUMAN; INCIDENCE; MACULAR EDEMA; OPTICAL COHERENCE TOMOGRAPHY; PREVALENCE; PROCEDURES; RISK FACTOR;

DIABETIC RETINOPATHY; DISEASE MANAGEMENT; GLOBAL HEALTH; HUMANS; INCIDENCE; MACULAR EDEMA; PREVALENCE; RISK FACTORS; TOMOGRAPHY, OPTICAL COHERENCE;

EID: 85016984595     PISSN: 02503751     EISSN: 16622790     Source Type: Book Series    
DOI: 10.1159/000455277     Document Type: Article

References (159)

1. King H, Aubert RE, Herman WH: Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998; 21: 1414-1431
2. Antonetti DA, Lieth E, Barber AJ, Gardner TW: Molecular mechanisms of vascular permeability in diabetic retinopathy. Semin Ophthalmol 1999; 14: 240-248
3. Early Treatment Diabetic Retinopathy Study Research Group: Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 1985; 103: 1796-1806
4. Weinberger D, Fink-Cohen S, Gaton D, Priel E, Yassur Y: Non-retinovascular leakage in diabetic maculopathy. Br J Ophthalmol 1995; 79: 728-731
5. Lewis H, Abrams GW, Blumenkranz MS, Campo RV: Vitrectomy for diabetic macular traction and edema associated with posterior hyaloidal traction. Ophthalmology 1992; 99: 753-759
6. Harbour JW, Smiddy WE, Flynn HWJ, Rubsamen PE: Vitrectomy for diabetic macular edema associated with a thickened and taut posterior hyaloid membrane. Am J Ophthalmol 1996; 121: 405-413
7. Kang SW, Park CY, Ham DI: The correlation between fluorescein angiographic and optical coherence tomographic features in clinically significant diabetic macular edema. Am J Ophthalmol 2004; 137: 313-322
8. Wilkinson CP, Ferris FL, Klein RE, Lee PP, Agardh CD, Davis M, Dills D, Kampik A, Pararajasegaran R, Verdaguer JT, Global Diabetic Retinopathy Project Group: Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology 2003; 110: 1677-1682
9. Girach A, Lund-Andersen H: Diabetic macular oedema: a clinical overview. Int J Clin Pract 2007; 61: 88-97
10. Williams R, Airey M, Baxter H, Forrester J, Kennedy-Martin T, Girach A: Epidemiology of diabetic retinopathy and macular oedema: a systemic review. Eye 2004; 18: 963-983
11. Varma R, Torres M, Pea F, Klein R, Azen S; Los Angeles Latino Eye Study Group: Prevalence of diabetic retinopathy in adult Latinos. Ophthalmology 2004; 111: 1298-1306
12. Brown JC, Solomon SD, Bressler SB, et al: Detection of diabetic foveal edema. Contact lens biomicroscopy compared with optical coherence tomography. Arch Opthalmol 2004; 122: 330-335
13. Massin P, Girach A, Erginay A, Gaudric A: Optical coherence tomography: a key to the future management of patients with diabetic macular oedema. Acta Ophthalmol Scand 2006; 84: 466-474
14. Otani T, Kishi S, Maruyama Y: Patterns of diabetic macular edema with optical coherence tomography. Am J Ophthalmol 1999; 127: 688-693
15. Bolz M, Schmidt-Erfurth U, Deak G, Mylonas G, Kriechbaum K, Scholda C: Optical coherence tomographic hyperreflective foci: a morphologic sign of lipid extravasation in diabetic macular edema. Ophthalmology 2009; 116: 914-920
16. Ozdemir H, Karacorlu M, Karacorlu S: Serous macular detachment in diabetic cystoid macular oedema. Acta Ophthalmol Scand 2005; 83: 63-66
17. Catier A, Tadayoni R, Paques M, et al: Optical coherence tomography characterization of macular edema according to various etiology. Am J Ophthalmol 2005; 140: 200-206
18. Gaucher D, Sebah C, Erginay A, et al: Optical coherence tomography features during the evolution of serous retinal detachment in patients with diabetic macular edema. Am J Ophthalmol 2008; 145: 289-296
19. Gaucher D, Tadayoni R, Erginay A, et al: Optical coherence tomography assessment of the vitreorelationship in diabetic macular edema. Am J Ophthalmol 2005; 139: 807-813
20. Massin P, Duguid G, Erginay A, et al: Optical coherence tomography for evaluating diabetic macular edema before and after vitrectomy. Am J Ophthalmol 2003; 135: 169-177
21. Thomas D, Bunce C, Moorman C, Laidlaw AH: Frequency and associations of a taut thickened posterior hyaloid, partial vitreomacular separation, and subretinal fluid in patients with diabetic macular edema. Retina 2005; 25: 883-888
22. Pendergast SD, Hassan TS, Williams GA, et al: Vitrectomy for diffuse diabetic macular edema associated with a taut premacular posterior hyaloid. Am J Ophthalmol 2000; 130: 178-186
23. Uchino E, Uemura A, Ohba N: Initial stages of posterior vitreous detachment in healthy eyes of older persons evaluated by optical coherence tomography. Arch Ophthalmol 2001; 119: 1475-1479
24. Hee MR, Puliafito CA, Wong C, Duker JS, Reichel E, Rutledge B, et al: Quantitative assessment of macular edema with optical coherence tomography. Arch Ophthalmol 1995; 113: 1019-1029
25. Hee MR, Puliafito CA, Duker JS, Reichel, E, Coker JG, Wilkins JR, et al: Topography of diabetic macular edema with optical coherence tomography. Ophthalmology 1998; 105: 360-370
26. Massin P, Haouchine B, Gaudric A: Macular traction detachment and diabetic edema associated with posterior hyaloidal traction. Am J Ophthalmol 2001; 132: 599-600
27. Polito A, Del Borrello M, Isola M, et al: Repeatability and reproducibility of fast macular thickness mapping using stratus optical coherence tomography. Arch Ophthalmol 2005; 123: 1330-1337
28. Wolf-Schnurrbusch UE, Ceklic L, Brinkmann CK, et al: Macular thickness measurements in healthy eyes using six different optical coherence tomography instruments. Invest Ophthalmol Vis Sci 2009; 50: 3432-3437
29. Menke MN, Dabov S, Knecht P, Sturm V: Reproducibility of retinal thickness measurements in healthy subjects using spectralis optical coherence tomography. Am J Ophthalmol 2009; 147: 467-472
30. Diabetic Retinopathy Clinical Research Network, Krzystolik MG, Strauber SF, Aiello LP, et al: Reproducibility of macular thickness and volume using Zeiss optical coherence tomography in patients with diabetic macular edema. Ophthalmology 2007; 114: 1520-1525
31. Strom C, Sander B, Larsen N, et al: Diabetic macular edema assessed with optical coherence tomography and stereo fundus photography. Invest Ophthalmol Vis Sci 2002; 43: 241-245
32. Klein R, Moss SE, Klein BE, et al: The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XI. The incidence of macular edema. Ophthalmology 1989; 96: 1501-1510
33. Klein R, Klein BE, Moss SE, Cruickshanks KJ: The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XV. The long-term incidence of macular edema. Ophthalmology 1995; 102: 7-16
34. Klein R, Klein BE, Moss SE, Cruickshanks KJ: The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. Ophthalmology 1998; 105: 1801-1815
35. Vitale S, Maguire MG, Murphy RP, et al: Clinically significant macular edema in type I diabetes: incidence and risk factors. Ophthalmology 1995; 102: 1170-1176
36. Diabetes Control and Complications Trial Research Group: Hypoglycemia in the Diabetes Control and Complications Trial. Diabetes 1997; 46: 271-286
37. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group: Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 2000; 342: 381-389
38. Aroca PR, Salvat M, Fernandez J, Mendez I: Risk factors for diffuse and focal macular edema. J Diabetes Complications 2004; 18: 211-215
39. Roy MS, Affouf M: Six-year progression of retinopathy and associated risk factors in African American patients with type 1 diabetes mellitus: the New Jersey 725. Arch Ophthalmol 2006; 124: 1297-1306
40. White NH, Sun W, Cleary PA, Danis RP, Davis MD, Hainsworth DP, Hubbard LD, Lachin JM, Nathan DM: Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial. Arch Ophthalmol 2008; 126: 1707-1715
41. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853
42. UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 708-713
43. Matthews DR, Stratton IM, Aldington SJ, et al: Risk of progression of retinopathy and visual loss related to tight control of blood pressure in type 2 diabetes mellitus (UKPDS 69). Arch Ophthalmol 2004; 122: 1631-1640
44. Kohner EM, Stratton IM, Aldington SJ, Holman RR, Matthews DR; UK Prospective Diabetes Study (UKPDS) Group: Relationship between the severity of retinopathy and progression to photocoagulation in patients with type 2 diabetes mellitus in the UKPDS (UKPDS 52). Diabet Med 2001; 18: 178-184
45. Kohner EM: Microvascular disease: what does the UKPDS tell us about diabetic retinopathy? Diabet Med 2008; 25: 20-24
46. Adler AI, Stratton IM, Neil HA, et al: Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000; 321: 412-419
47. Klein R, Knudtson MD, Lee KE, et al: The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXIII. The twentyfive-year incidence of macular edema in persons with type 1 diabetes. Ophthalmology 2009; 116: 497-503
48. Sarao V, Veritti D, Lanzetta P: Regression of diabetic macular edema after subcutaneous exenatide. Acta Diabetol 2014; 51: 505-508
49. Varadhan L, Humphreys T, Walker AB, Varughese GI: The impact of improved glycemic control with GLP-1 receptor agonist therapy on diabetic retinopathy. Diabetes Res Clin Pract 2014; 103:e37-e39
50. Davis MD, Beck RW, Home PD, Sandow J, Ferris FL: Early retinopathy progression in four randomized trials comparing insulin glargine and NPH (corrected) insulin. Exp Clin Endocrinol Diabetes 2007; 115: 240-243
51. Jaross N, Ryan P, Newland H: Incidence and progression of diabetic retinopathy in an Aboriginal Australian population: results from the Katherine Region Diabetic Retinopathy Study (KRDRS). Report No. 2. Clin Exp Ophthalmol 2005; 33: 26-33
52. Funatsu H, Yamashita H: Pathogenesis of diabetic retinopathy and the reninangiotensin system. Ophthalmic Physiol Opt 2003; 23; 495-501
53. Sjolie AK: Prospects for angiotensin receptor blockers in diabetic retinopathy. Diabetes Res Clin Pract 2007; 76:S31-S39
54. West KM, Erdreich LJ, Stober JA: A detailed study of risk factors for retinopathy and nephropathy in diabetes. Diabetes 1980; 29: 501-508
55. Knuiman MW, Welborn TA, McCann VJ, et al: Prevalence of diabetic complications in relation to risk factors. Diabetes 1986; 35: 1332-1339
56. Jerneld B: Prevalence of diabetic retinopathy: a population study from the Swedish island of Gotland. Acta Ophthalmol 1988; 188: 3-32
57. Kostraba JN, Klein R, Dorman JS, et al: The Epidemiology of Diabetes Complications Study. IV. Correlates of diabetic background and proliferative retinopathy. Am J Epidemiol 1991; 133: 381-391
58. Cruickshanks KJ, Ritter LL, Klein R, Moss SE: The association of microalbuminuria with diabetic retinopathy: the Wisconsin Epidemiologic Study of Diabetic Retinopathy. Ophthalmology 1993; 100: 862-867
59. Klein R, Moss SE, Klein BE: Is gross proteinuria a risk factor for the incidence of proliferative diabetic retinopathy? Ophthalmology 1993; 100: 1140-1146
60. Romero P, Baget M, Mendez I, et al: Diabetic macular edema and its relationship to renal microangiopathy: a sample of type I diabetes mellitus patients in a 15-year follow-up study. J Diabetes Complications 2007; 21: 172-180
61. Klein R, Klein BE, Davis MD: Is cigarette smoking associated with diabetic retinopathy? Am J Epidemiol 1983; 118: 228-238
62. Moss SE, Klein R, Klein BE: Cigarette smoking and ten-year progression of diabetic retinopathy. Ophthalmology 1996; 103: 1438-1442
63. Chew EY, Klein ML, Ferris FL III, et al: Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. Arch Ophthalmol 1996; 114: 1079-1084
64. Sen K, Misra A, Kumar A, Pandey RM: Simvastatin retards progression of retinopathy in diabetic patients with hypercholesterolemia. Diabetes Res Clin Pract 2002; 56: 1-11
65. Rechtman E, Harris A, Garzozi HJ, Ciulla TA: Pharmacologic therapies for diabetic retinopathy and diabetic macular edema. Clin Ophthalmol 2007; 1: 383-391
66. Lee CM, Olk RJ: Modified grid laser photocoagulation for diffuse diabetic macular edema. Long-term visual results. Ophthalmology 1991; 98: 1594-1602
67. Sarao V, Veritti D, Boscia F, Lanzetta P: Intravitreal steroids for the treatment of retinal diseases. ScientificWorldJournal 2014; 2014: 989501
68. Tsaprouni LG, Ito K, Punchard N, Adcock IM: Triamcinolone acetonide and dexamethasome suppress TNF-alphainduced histone H4 acetylation on lysine residues 8 and 12 in mononuclear cells. Ann NY Acad Sci 2002; 973: 481-483
69. Juergens UR, Jager F, Darlath W, Stober M, Vetter H, Gillissen A: Comparison of in vitro activity of commonly used topical glucocorticoids on cytokine-and phospholipase inhibition. Eur J Med Res 2004; 9: 383-390
70. Tong JP, Lam DS, Chan WM, Choy KW, Chan KP, Pang CP: Effects of triamcinolone on the expression of VEGF and PEDF in human retinal pigment epithelial and human umbilical vein endothelial cells. Mol Vis 2006; 12: 1490-1495
71. Kim YH, Choi MY, Kim YS, et al: Triamcinolone acetonide protects the rat retina from STZ-induced acute inflammation and early vascular leakage. Life Sci 2007; 81: 1167-1173
72. Zhang SX, Wang JJ, Gao G, Shao C, Mott R, Ma JX: Pigment epithelium-derived factor (PEDF) is an endogenous antiinflammatory factor. FASEB J 2006; 20: 323-325
73. Abelson MB, Butrus S: Corticosteroids in ophthalmic practice; in Abelson MB, Neufeld AH, Topping TM (eds): Principles and Practice of Ophthalmology. Philadelphia, WB Saunders, 1994, p 1014
74. Mizuno S, Nishiwaki A, Morita H, Miyake T, Ogura Y: Effects of periocular administration of triamcinolone acetonide on leukocyte-endothelium interactions in the ischemic retina. Invest Ophthalmol Vis Sci 2007; 48: 2831-2836
75. Audren F, Erginay A, Haouchine B, et al: Intravitreal triamcinolone acetonide for diffuse macular oedema: 6-month results of a prospective controlled trial. Acta Ophthalmol Scand 2006; 84: 624-630
76. Jonas JB, Kamppeter BA, Harder B, Vossmerbaeumer U, Sauder G, Spandau UH: Intravitreal triamcinolone acetonide for diabetic macular edema: a prospective, randomized study. J Ocul Pharmacol Ther 2006; 22: 200-207
77. Gillies MC, Sutter FK, Simpson JM, Larsson J, Ali H, Zhu M: Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double masked, placebo-controlled, randomized clinical trial. Ophthalmology 2006; 113: 1533-1538
78. Diabetic Retinopathy Clinical Research Network: A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology 2008; 115: 1447-1449, 1449.e1-e10
79. Diabetic Retinopathy Clinical Research Network, Elman MJ, Aiello LP, et al: Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010; 117: 1064-1077.e35
80. Jager RD, Aiello LP, Patel SC, Cunningham ET Jr: Risks of intravitreous injection: a comprehensive review. Retina 2004; 24: 676-698
81. Veritti D , Perissin L , Zorzet S , Lanzetta P: The effect of triamcinolone acetonide, sodium hyaluronate, and chondroitin sulfate on human endothelial cells: an in vitro study. Eur J Ophthalmol 2011; 21(suppl 6):S75-S79
82. Geroski DH, Edelhauser HF: Transscleral drug delivery for posterior segment disease. Adv Drug Deliv Rev 2001; 52: 37-48
83. Olsen TW, Edelhauser HF, Lim JI, Geroski DH: Human scleral permeability. Effects of age, cryotherapy, transscleral diode laser, and surgical thinning. Invest Ophthalmol Vis Sci 1995; 36: 1893-1903
84. Kato A, Kimura H, Okabe K, Okabe J, Kunou N, Ogura Y: Feasibility of drug delivery to the posterior pole of the rabbit eye with an episcleral implant. Invest Ophthalmol Vis Sci 2004; 45: 238-244
85. Bonini-Filho MA, Jorge R, Barbosa JC, Calucci D, Cardillo JA, Costa RA: Intravitreal injection versus sub-Tenons infusion of triamcinolone acetonide for refractory diabetic macular edema: a randomized clinical trial. Invest Ophthalmol Vis Sci 2005; 46: 3845-3849
86. Cardillo JA, Melo LA Jr, Costa RA, et al: Comparison of intravitreal versus posterior sub-Tenons capsule injection of triamcinolone acetonide for diffuse diabetic macular edema. Ophthalmology 2005; 112: 1557-1563
87. Ozdek S, Bahceci UA, Gurelik G, Hasanreisoglu B: Posterior subtenon and intravitreal triamcinolone acetonide for diabetic macular edema. J Diabetes Complications 2006; 20: 246-251
88. Veritti D, Lanzetta P, Perissin L, Bandello F: Posterior juxtascleral infusion of modified triamcinolone acetonide formulation for refractory diabetic macular edema: one-year follow-up. Invest Ophthalmol Vis Sci 2009; 50: 2391-2397
89. Graham RO, Peyman GA: Intravitreal injection of dexamethasone. Treatment of experimentally induced endophthalmitis. Arch Ophthalmol 1974; 92: 149-154
90. Hardman JG, Limbird LE, Molinoff PB: Goodman & Gilmans The Pharmacological Basis of Therapeutics, ed 9. New York, McGraw Hill, 2001
91. Fialho SL, Behar-Cohen F, Silva-Cunha A: Dexamethasone-loaded poly(epsiloncaprolactone) intravitreal implants: a pilot study. Eur J Pharm Biopharm 2008; 68: 637-646
92. Boyer DS, et al: Three-year randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology 2014; 121: 1904-1914
93. Ashton P, Blandford DL, Pearson PA, Jaffe GJ, Martin DF, Nussenblatt RB: Review: implants. J Ocul Pharmacol 1994; 10: 691-701
94. Jaffe GJ, Yang CH, Guo H, Denny JP, Lima C, Ashton P: Safety and pharmacokinetics of an intraocular fluocinolone acetonide sustained delivery device. Invest Ophthalmol Vis Sci 2000; 41: 3569-3575
95. Campochiaro PA, et al: Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology 2011; 118: 626-635.e2
96. Campochiaro PA, et al: Sustained delivery fluocinolone vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology 2012; 119: 2125-2132
97. Hu M, Huang G, Karasina F, Wong VG: Verisome, a novel injectable, sustained release, biodegradable, intraocular drug delivery system and triamcinolone acetonide. Annu Meet Assoc Res Vis Ophthalmol, Ft Lauderdale, 2008
98. Lim JI, et al: Sustained-release intravitreal liquid drug delivery using triamcinolone acetonide for cystoid macular edema in retinal vein occlusion. Ophthalmology 2011; 118: 1416-1422
99. Gardner TW, Antonetti DA, Barber AJ, LaNoue KF, Levison SW: Diabetic retinopathy: more than meets the eye. Surv Ophthalmol 2002; 47(suppl 2):S253-S262
100. Grant MB, Afzal A, Spoerri P, Pan H, Shaw LC, Mames RN: The role of growth factors in the pathogenesis of diabetic retinopathy. Expert Opin Investig Drugs 2004; 13: 1275-1293
101. Nguyen QD, et al: Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology: 2012; 119: 789-801
102. Brown DM, et al: Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology 2013; 120: 2013-2022
103. Mitchell P, et al: The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 2011; 118: 615-625
104. Schmidt-Erfurth U, et al: Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study. Ophthalmology 2014; 121: 1045-1053
105. Writing Committee for the Diabetic Retinopathy Clinical Research Network, Gross JG, et al: Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized trial. JAMA, 2015, 314, 2137-2146.
106. Korobelnik JF, et al: Intravitreal aflibercept for diabetic macular edema. Ophthalmology 2014; 121: 2247-2254
107. Scott IU, Edwards AR, Beck RW, et al: A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology 2007; 114: 1860-1867
108. Ahmadieh H, Ramezani A, Shoeibi N, et al: Intravitreal bevacizumab with or without triamcinolone for refractory macular edema: a placebo-controlled, randomized clinical trial. Graefes Arch Clin Exp Ophthalmol 2008; 246: 483-489
109. Soheilian M, Ramezani A, Obudi A, et al: Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology 2009; 116: 1142-1150
110. Paccola L, Costa RA, Folgosa MS, Barbosa JC, Scott IU, Jorge R: Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema (IBEME study). Br J Ophthalmol 2008; 92: 76-80
111. Diabetic Retinopathy Clinical Research Network, Wells JA, et al: Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med 2015; 372: 1193-1203
112. Wells JA, et al: Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology 2016; 123: 1351-1359
113. Jittpoonkuson T, Garcia P, Rosen RB: Correlation between fluorescein angiography and spectral domain optical coherence tomography in the diagnosis of cystoid macular edema. Br J Ophthalmol 2010; 94: 1197-1200
114. Bandello F, Polito A, Del Borrello M, Zemella N, Isola M: Light versus classic laser treatment for clinically significant diabetic macular oedema. Br J Ophthalmol 2005; 89: 864-870
115. Stefansson E: The therapeutic effects of retinal laser treatment and vitrectomy. A theory based on oxygen and vascular physiology. Acta Ophthalmol Scand 2001; 79: 435-440
116. Wolbarsht ML, Landers MB 3rd: The rationale of photocoagulation therapy for proliferative diabetic retinopathy: a review and a model. Ophthalmic Surg 1980; 11: 235-245
117. Molnar I, Poitry S, Tsacopoulos M, et al: Effect of laser photocoagulation on oxygenation of the retina in miniature pigs. Invest Ophthalmol Vis Sci 1985; 26: 1410-1414
118. Stefansson E, Landers MB 3rd, Wolbarsht ML: Increased retinal oxygen supply following pan-retinal photocoagulation and vitrectomy and lensectomy. Trans Am Acad Ophthalmol Soc 1981; 79: 307-334
119. Yu D, Cringle S, Su E, Yu PK, Humayun MS, Dorin G: Laser-induced changes in intraretinal oxygen distribution in pigmented rabbits. Invest Ophthalmol Vis Sci 2005; 46: 988-999
120. Wilson DJ, Finkelstein D, Quigley HA, Green WR: Macular grid photocoagulation. An experimental study on the primate retina. Arch Ophthalmol 1988; 106: 100-105
121. Guyer DR, DAmico DJ, Smith CW: Subretinal fibrosis after laser photocoagulation for diabetic macular edema. Am J Ophthalmol 1992; 113: 652-656
122. Han DP, Mieler WF, Burton TC: Submacular fibrosis after photocoagulation for diabetic macular edema. Am J Ophthalmol 1992; 113: 513-521
123. Gottfredsdottir MS, Stefansson E, Jonasson F, Gislason I: Retinal vasoconstriction after laser treatment for diabetic macular edema. Am J Ophthalmol 1993; 115: 64-67
124. Xiao M, McLeod D, Cranley J, Williams G, Boulton M: Growth factor staining patterns in the pig retina following retinal laser photocoagulation. Br J Ophthalmol 1999; 83: 728-736
125. Ogata N, Ando A, Uyama M, Matsumura M: Expression of cytokines and transcription factors in photocoagulated human retinal pigment epithelial cells. Graefes Arch Clin Exp Ophthalmol 2001; 239: 87-95
126. Early Treatment Diabetic Retinopathy Study Research Group: Focal photocoagulation treatment of diabetic macular edema. Relationship of treatment effect to fluorescein angiographic and other retinal characteristics at baseline. ETDRS report number 19. Arch Ophthalmol. 1995, 113, 1144-1155.
127. Early Treatment Diabetic Retinopathy Study Research Group: Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 2. Ophthalmology 1987; 94: 761-774
128. Ferris FL III, Davis MD: Treating 20/20 eyes with diabetic macular edema. Arch Ophthalmol 1999; 117: 675-676
129. Olk RJ: Modified grid argon (bluegreen) laser photocoagulation for diffuse diabetic macular edema. Ophthalmology 1986; 93: 938-950
130. Olk RJ: Argon green (514 nm) versus krypton red (647 nm) modified grid laser photocoagulation for diffuse diabetic macular edema. Ophthalmology 1990; 97: 1101-1113
131. Writing Committee for the Diabetic Retinopathy Clinical Research Network: Comparison of modified early treatment diabetic retinopathy study and mild macular grid laser photocoagulation strategies for diabetic macular edema. Arch Ophthalmol 2007; 125: 469-480
132. Lewis H, Schachat AP, Haimann MH, et al: Choroidal neovascularization after laser photocoagulation for diabetic macular edema. Ophthalmology 1990; 97: 503-511
133. Schatz H, Madeira D, McDonald R: Progressive enlargement of laser scars following grid laser photocoagulation for diffuse diabetic macular edema. Arch Ophthalmol 1991; 109: 1549-1551
134. Fong DS, Segal PP, Myers F, et al: Subretinal fibrosis in diabetic macular edema. ETDRS report 23. Early Treatment Diabetic Retinopathy Study Research Group. Arch Ophthalmol 1997; 115: 873-877
135. Lanzetta P, Dorin G, Pirracchio A, Bandello F: Theoretical bases of nonophthalmoscopically visible endpoint photocoagulation. Semin Ophthalmol 2001; 16: 8-11
136. Dorin G: Subthreshold and micropulse diode laser photocoagulation. Semin Ophthalmol 2003; 18: 147-153
137. Lanzetta P, Polito A, Veritti D: Subthreshold laser. Ophthalmology 2008; 115: 216-216.e1
138. Veritti D, et al: Online optical coherence tomography during subthreshold laser irradiation. Eur J Ophthalmol 2012; 22: 575-579
139. Chen G, Tzekov R, Li W, Jiang F, Mao S, Tong Y: Subthreshold micropulse diode laser versus conventional laser photocoagulation for diabetic macular edema: a meta-analysis of randomized controlled trials. Retina 2016; 36: 2059-2065
140. Brinkmann R, Roider J, Birngruber R: Selective retina therapy (SRT): a review on methods, techniques, preclinical and first clinical results. Bull Soc Belge Ophtalmol 2006; 302: 51-69
141. Framme C, Schuele G, Kobuch K, Flucke B, Birngruber R, Brinkmann R: Investigation of selective retina treatment (SRT) by means of 8 ns laser pulses in a rabbit model. Lasers Surg Med 2008; 40: 20-27
142. Framme C, Walter A, Prahs P, Theisen-Kunde D, Brinkmann R: Comparison of threshold irradiances and online dosimetry for selective retina treatment (SRT) in patients treated with 200 nanoseconds and 1.7 microseconds laser pulses. Lasers Surg Med 2008; 40: 616-624
143. Park YG, Kim JR, Kang S, Seifert E, Theisen-Kunde D, Brinkmann R, Roh YJ: Safety and efficacy of selective retina therapy (SRT) for the treatment of diabetic macular edema in Korean patients. Graefes Arch Clin Exp Ophthalmol 2016; 254: 1703-1713
144. Hamilton P: Selective laser retinal pigment epithelium treatment for diabetic macular edema. Retina Subspecialty Day AAO Annu Meet, New Orleans, 2007
145. Blumenkranz MS, Yellachich D, Andersen DE, et al: Semiautomated patterned scanning laser for retinal photocoagulation. Retina 2006; 26: 370-376
146. Sheth S, Lanzetta P, Veritti D, Zucchiatti I, Savorgnani C, Bandello F: Experience with the Pascal photocoagulator: an analysis of over 1,200 laser procedures with regard to parameter refinement. Indian J Ophthalmol 2011; 59: 87-91
147. Van Effenterre G, et al: Macular edema caused by contraction of the posterior hyaloids in diabetic retinopathy. Surgical treatment of a series of 22 cases (in French). J Fr Ophthalmol 1993; 16: 602-610
148. Gandorfer A, Messmer EM, Ulbig MW, Kampik A: Resolution of diabetic macular edema after surgical removal of the posterior hyaloid and the inner limiting membrane. Retina 2000; 20: 126-133
149. Ikeda T, Sato K, Katano T, Hayashi Y: Vitrectomy for cystoid macular oedema with attached posterior hyaloid membrane in patients with diabetes. Br J Ophthalmol 1999; 83: 12-14
150. Ikeda T, Sato K, Katano T, Hayashi Y: Improved visual acuity following pars plana vitrectomy for diabetic cystoid macular edema and detached posterior hyaloid. Retina 2000; 20: 220-222
151. Otani T, Kishi S: Tomographic assessment of vitreous surgery for diabetic macular edema. Am J Ophthalmol 2000; 129: 487-494
152. Yamamoto T, Akabane N, Takeuchi S: Vitrectomy for diabetic macular edema: the role of posterior vitreous detachment and epimacular membrane. Am J Ophthalmol 2001; 132: 369-377
153. Kumar A, Sinha S, Azad R, Sharma YR, Vohra R: Comparative evaluation of vitrectomy and dye-enhanced ILM peel with grid laser in diffuse diabetic macular edema. Graefes Arch Clin Exp Ophthalmol 2007; 245: 360-368
154. Patel JI, Hykin PG, Schadt M, et al: Diabetic macular oedema: pilot randomised trial of pars plana vitrectomy vs macular argon photocoagulation. Eye (Lond) 2006; 20: 873-881
155. Stolba U, Binder S, Gruber D, Krebs I, Aggermann T, Neumaier B: Vitrectomy for persistent diffuse diabetic macular edema. Am J Ophthalmol 2005; 140: 295-301
156. Thomas D, Bunce C, Moorman C, Laidlaw DA: A randomized controlled feasibility trial of vitrectomy versus laser for diabetic macular oedema. Br J Ophthalmol 2005; 89: 81-86
157. Yanyali A, Nohutcu AF, Horozoglu F, Celik E: Modified grid laser photocoagulation versus pars plana vitrectomy with internal limiting membrane removal in diabetic macular edema. Am J Ophthalmol 2005; 139: 795-801
158. Massin-Korobelnik P, Gaudric A, Coscas G: Spontaneous evolution and treatment of diabetic cystoid macular edema. Graefes Arch Ophthalmol 1994; 232: 279-289
159. Polito A, Borello M, Polini G, et al: Diurnal variation in clinically significant diabetic macular edema measured by the Stratus OCT. Retina 2006; 26: 14-20